semaglutide albumin binding Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes | Reviews in Endocrine and Metabolic Disorders Pharmacokinetic Properties of a Once-Weekly

Contraindications Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [seeWarnings and Precautions (5.1)]

Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention

If it works for you, the expected effect is more along the lines of: modest shifts in fat loss over weeks to months, not dramatic weekly scale drops

This "leftover" unabsorbed material in the gut can contribute to the bloating and gas that make some users feel sick